JOINT-STOCK COMPANY "BIOKAD" registered new pegylated interferon from multiple sclerosis

JOINT-STOCK COMPANY "BIOKAD" received a regudostovereniye on pegylated Rekombinantny interferon beta-1 – Teneksia. It is peginterferon beta 1a, connected with a polyethyleneglycol molecule. As report in companies, conjugation with polyethyleneglycol improves pharmacokinetic characteristics of a preparation. Preparation MNN – sampeginterferon beta 1a. It is intended for therapy of patients with remittiruyushchy multiple sclerosis. JOINT-STOCK COMPANY "BIOKAD" developed a preparation since 2012. Market size pegylated interferonov for treatment of multiple sclerosis in companies estimate at 2 billion rubles. Conjugation of peginterferon beta 1a with a molecule...